XML 70 R46.htm IDEA: XBRL DOCUMENT
v3.22.4

Segments of Business and Geographic Areas (Tables) | 12 Months Ended
--- | ---
Jan. 01, 2023 | Jan. 02, 2022
Segment Reporting [Abstract] |  |
Schedule of Sales by Segment of Business |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2022 |  | 2021 |  | 2020 |  | ’22 vs. ’21 |  | ’21 vs. ’20
CONSUMER HEALTH (1) |  |  |  |  |  |  |  |  |  |
OTC |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 2,782 |  |  | 2,594 |  |  | 2,460 |  |  | 7.3 | % |  | 5.4 |
International |  | 3,249 |  |  | 3,034 |  |  | 2,761 |  |  | 7.1 |  |  | 9.9 |
Worldwide |  | 6,031 |  |  | 5,627 |  |  | 5,221 |  |  | 7.2 |  |  | 7.8 |
Skin Health/Beauty |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,337 |  |  | 2,400 |  |  | 2,350 |  |  | (2.6) |  |  | 2.1 |
International |  | 2,015 |  |  | 2,141 |  |  | 2,100 |  |  | (5.9) |  |  | 1.9 |
Worldwide |  | 4,352 |  |  | 4,541 |  |  | 4,450 |  |  | (4.2) |  |  | 2.0 |
Oral Care |  |  |  |  |  |  |  |  |  |
U.S. |  | 635 |  |  | 637 |  |  | 683 |  |  | (0.3) |  |  | (6.7) |
International |  | 871 |  |  | 1,008 |  |  | 958 |  |  | (13.6) |  |  | 5.1 |
Worldwide |  | 1,505 |  |  | 1,645 |  |  | 1,641 |  |  | (8.5) |  |  | 0.2 |
Baby Care |  |  |  |  |  |  |  |  |  |
U.S. |  | 357 |  |  | 378 |  |  | 376 |  |  | (5.5) |  |  | 0.5 |
International |  | 1,104 |  |  | 1,188 |  |  | 1,141 |  |  | (7.1) |  |  | 4.1 |
Worldwide |  | 1,461 |  |  | 1,566 |  |  | 1,517 |  |  | (6.7) |  |  | 3.2 |
Women's Health |  |  |  |  |  |  |  |  |  |
U.S. |  | 13 |  |  | 13 |  |  | 13 |  |  | 1.7 |  |  | (1.6) |
International |  | 891 |  |  | 905 |  |  | 888 |  |  | (1.5) |  |  | 1.8 |
Worldwide |  | 904 |  |  | 917 |  |  | 901 |  |  | (1.5) |  |  | 1.8 |
Wound Care/Other |  |  |  |  |  |  |  |  |  |
U.S. |  | 475 |  |  | 495 |  |  | 480 |  |  | (4.0) |  |  | 3.1 |
International |  | 224 |  |  | 243 |  |  | 240 |  |  | (8.0) |  |  | 1.7 |
Worldwide |  | 700 |  |  | 739 |  |  | 720 |  |  | (5.3) |  |  | 2.6 |
TOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |
U.S. |  | 6,599 |  |  | 6,516 |  |  | 6,362 |  |  | 1.3 |  |  | 2.4 |
International |  | 8,354 |  |  | 8,519 |  |  | 8,088 |  |  | (1.9) |  |  | 5.3 |
Worldwide |  | 14,953 |  |  | 15,035 |  |  | 14,450 |  |  | (0.5) |  |  | 4.0 |
PHARMACEUTICAL(1) |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |
U.S. |  | 11,036 |  |  | 10,843 |  |  | 10,175 |  |  | 1.8 |  |  | 6.6 |
International |  | 5,899 |  |  | 5,907 |  |  | 4,880 |  |  | (0.1) |  |  | 21.0 |
Worldwide |  | 16,935 |  |  | 16,750 |  |  | 15,055 |  |  | 1.1 |  |  | 11.3 |
REMICADE |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,417 |  |  | 2,019 |  |  | 2,508 |  |  | (29.8) |  |  | (19.5) |
U.S. Exports |  | 204 |  |  | 236 |  |  | 346 |  |  | (13.6) |  |  | (31.9) |
International |  | 722 |  |  | 935 |  |  | 893 |  |  | (22.8) |  |  | 4.8 |
Worldwide |  | 2,343 |  |  | 3,190 |  |  | 3,747 |  |  | (26.6) |  |  | (14.9) |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,166 |  |  | 1,127 |  |  | 1,155 |  |  | 3.5 |  |  | (2.4) |
International |  | 1,017 |  |  | 1,148 |  |  | 1,088 |  |  | (11.4) |  |  | 5.5 |
Worldwide |  | 2,184 |  |  | 2,276 |  |  | 2,243 |  |  | (4.0) |  |  | 1.4 |
STELARA |  |  |  |  |  |  |  |  |  |
U.S. |  | 6,388 |  |  | 5,938 |  |  | 5,240 |  |  | 7.6 |  |  | 13.3 |
International |  | 3,335 |  |  | 3,196 |  |  | 2,467 |  |  | 4.4 |  |  | 29.6 |
Worldwide |  | 9,723 |  |  | 9,134 |  |  | 7,707 |  |  | 6.5 |  |  | 18.5 |
TREMFYA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,844 |  |  | 1,503 |  |  | 926 |  |  | 22.7 |  |  | 62.3 |
International |  | 824 |  |  | 624 |  |  | 421 |  |  | 32.0 |  |  | 48.2 |
Worldwide |  | 2,668 |  |  | 2,127 |  |  | 1,347 |  |  | 25.4 |  |  | 57.9 |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |
U.S. |  | 17 |  |  | 21 |  |  | — |  |  | (18.4) |  |  | **
International |  | 0 |  |  | 3 |  |  | 11 |  |  | ** |  | (73.3) |
Worldwide |  | 17 |  |  | 24 |  |  | 11 |  |  | (28.2) |  |  | **
Infectious Diseases |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,680 |  |  | 2,249 |  |  | 1,735 |  |  | (25.3) |  |  | 29.7 |
International |  | 3,769 |  |  | 3,576 |  |  | 1,808 |  |  | 5.4 |  |  | 97.8 |
Worldwide |  | 5,449 |  |  | 5,825 |  |  | 3,543 |  |  | (6.5) |  |  | 64.4 |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |
U.S. |  | 120 |  |  | 634 |  |  | — |  |  | (81.1) |  |  | **
International |  | 2,059 |  |  | 1,751 |  |  | — |  |  | 17.6 |  |  | **
Worldwide |  | 2,179 |  |  | 2,385 |  |  | — |  |  | (8.6) |  |  | **
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |
U.S. |  | 36 |  |  | 41 |  |  | 44 |  |  | (10.8) |  |  | (7.6) |
International |  | 972 |  |  | 953 |  |  | 920 |  |  | 2.0 |  |  | 3.6 |
Worldwide |  | 1,008 |  |  | 994 |  |  | 964 |  |  | 1.5 |  |  | 3.1 |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,494 |  |  | 1,508 |  |  | 1,587 |  |  | (1.0) |  |  | (4.9) |
International |  | 449 |  |  | 575 |  |  | 597 |  |  | (21.9) |  |  | (3.6) |
Worldwide |  | 1,943 |  |  | 2,083 |  |  | 2,184 |  |  | (6.7) |  |  | (4.6) |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |
U.S. |  | 30 |  |  | 66 |  |  | 104 |  |  | (55.5) |  |  | (36.0) |
International |  | 289 |  |  | 297 |  |  | 292 |  |  | (2.6) |  |  | 1.7 |
Worldwide |  | 318 |  |  | 363 |  |  | 396 |  |  | (12.3) |  |  | (8.3) |
Neuroscience |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,570 |  |  | 3,347 |  |  | 3,091 |  |  | 6.7 |  |  | 8.3 |
International |  | 3,323 |  |  | 3,641 |  |  | 3,435 |  |  | (8.7) |  |  | 6.0 |
Worldwide |  | 6,893 |  |  | 6,988 |  |  | 6,526 |  |  | (1.4) |  |  | 7.1 |
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |
U.S. |  | 151 |  |  | 172 |  |  | 183 |  |  | (12.5) |  |  | (5.8) |
International |  | 493 |  |  | 495 |  |  | 439 |  |  | (0.4) |  |  | 12.8 |
Worldwide |  | 644 |  |  | 667 |  |  | 622 |  |  | (3.5) |  |  | 7.3 |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,714 |  |  | 2,550 |  |  | 2,314 |  |  | 6.5 |  |  | 10.2 |
International |  | 1,426 |  |  | 1,472 |  |  | 1,339 |  |  | (3.1) |  |  | 10.0 |
Worldwide |  | 4,140 |  |  | 4,022 |  |  | 3,653 |  |  | 3.0 |  |  | 10.1 |
RISPERDAL CONSTA |  |  |  |  |  |  |  |  |  |
U.S. |  | 257 |  |  | 287 |  |  | 296 |  |  | (10.4) |  |  | (2.9) |
International |  | 228 |  |  | 305 |  |  | 346 |  |  | (25.3) |  |  | (11.8) |
Worldwide |  | 485 |  |  | 592 |  |  | 642 |  |  | (18.1) |  |  | (7.7) |
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |
U.S. |  | 447 |  |  | 338 |  |  | 298 |  |  | 32.4 |  |  | 13.3 |
International |  | 1,176 |  |  | 1,368 |  |  | 1,312 |  |  | (14.1) |  |  | 4.3 |
Worldwide |  | 1,623 |  |  | 1,706 |  |  | 1,610 |  |  | (4.9) |  |  | 6.0 |
Oncology |  |  |  |  |  |  |  |  |  |
U.S. |  | 6,930 |  |  | 5,958 |  |  | 5,092 |  |  | 16.3 |  |  | 17.0 |
International |  | 9,052 |  |  | 8,590 |  |  | 7,275 |  |  | 5.4 |  |  | 18.1 |
Worldwide |  | 15,983 |  |  | 14,548 |  |  | 12,367 |  |  | 9.9 |  |  | 17.6 |
DARZALEX |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,210 |  |  | 3,169 |  |  | 2,232 |  |  | 32.8 |  |  | 42.0 |
International |  | 3,767 |  |  | 2,854 |  |  | 1,958 |  |  | 32.0 |  |  | 45.8 |
Worldwide |  | 7,977 |  |  | 6,023 |  |  | 4,190 |  |  | 32.4 |  |  | 43.8 |
ERLEADA |  |  |  |  |  |  |  |  |  |
U.S. |  | 968 |  |  | 813 |  |  | 583 |  |  | 19.2 |  |  | 39.3
International |  | 913 |  |  | 478 |  |  | 176 |  |  | ** |  | * *
Worldwide |  | 1,881 |  |  | 1,291 |  |  | 760 |  |  | 45.7 |  |  | 70.0 |
IMBRUVICA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,390 |  |  | 1,747 |  |  | 1,821 |  |  | (20.4) |  |  | (4.0) |
International |  | 2,394 |  |  | 2,622 |  |  | 2,307 |  |  | (8.7) |  |  | 13.6 |
Worldwide |  | 3,784 |  |  | 4,369 |  |  | 4,128 |  |  | (13.4) |  |  | 5.8 |
ZYTIGA /abiraterone acetate |  |  |  |  |  |  |  |  |  |
U.S. |  | 74 |  |  | 119 |  |  | 373 |  |  | (37.8) |  |  | (68.1) |
International |  | 1,696 |  |  | 2,178 |  |  | 2,097 |  |  | (22.1) |  |  | 3.9 |
Worldwide |  | 1,770 |  |  | 2,297 |  |  | 2,470 |  |  | (22.9) |  |  | (7.0) |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |
U.S. |  | 289 |  |  | 110 |  |  | 83 |  |  | ** |  | 31.7 |
International |  | 283 |  |  | 458 |  |  | 738 |  |  | (38.3) |  |  | (37.9) |
Worldwide |  | 571 |  |  | 568 |  |  | 821 |  |  | 0.6 |  |  | (30.8) |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,346 |  |  | 2,365 |  |  | 2,133 |  |  | (0.8) |  |  | 10.9 |
International |  | 1,071 |  |  | 1,085 |  |  | 1,015 |  |  | (1.3) |  |  | 6.9 |
Worldwide |  | 3,417 |  |  | 3,450 |  |  | 3,148 |  |  | (1.0) |  |  | 9.6 |
OPSUMIT |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,132 |  |  | 1,147 |  |  | 1,008 |  |  | (1.3) |  |  | 13.7 |
International |  | 651 |  |  | 672 |  |  | 631 |  |  | (3.2) |  |  | 6.6 |
Worldwide |  | 1,783 |  |  | 1,819 |  |  | 1,639 |  |  | (2.0) |  |  | 11.0 |
UPTRAVI |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,104 |  |  | 1,056 |  |  | 955 |  |  | 4.5 |  |  | 10.5 |
International |  | 218 |  |  | 181 |  |  | 138 |  |  | 20.4 |  |  | 31.1 |
Worldwide |  | 1,322 |  |  | 1,237 |  |  | 1,093 |  |  | 6.9 |  |  | 13.1 |
OTHER |  |  |  |  |  |  |  |  |  |
U.S. |  | 110 |  |  | 163 |  |  | 169 |  |  | (32.3) |  |  | (3.7) |
International |  | 202 |  |  | 232 |  |  | 247 |  |  | (12.8) |  |  | (5.9) |
Worldwide |  | 313 |  |  | 395 |  |  | 416 |  |  | (20.8) |  |  | (5.0) |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,042 |  |  | 3,192 |  |  | 3,509 |  |  | (4.7) |  |  | (9.0) |
International |  | 845 |  |  | 927 |  |  | 1,025 |  |  | (8.9) |  |  | (9.6) |
Worldwide |  | 3,887 |  |  | 4,119 |  |  | 4,534 |  |  | (5.6) |  |  | (9.2) |
XARELTO |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,473 |  |  | 2,438 |  |  | 2,345 |  |  | 1.4 |  |  | 4.0 |
International |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Worldwide |  | 2,473 |  |  | 2,438 |  |  | 2,345 |  |  | 1.4 |  |  | 4.0 |
INVOKANA/ INVOKAMET |  |  |  |  |  |  |  |  |  |
U.S. |  | 193 |  |  | 308 |  |  | 564 |  |  | (37.4) |  |  | (45.4) |
International |  | 255 |  |  | 254 |  |  | 231 |  |  | 0.1 |  |  | 9.9 |
Worldwide |  | 448 |  |  | 563 |  |  | 795 |  |  | (20.4) |  |  | (29.3) |
OTHER(2) |  |  |  |  |  |  |  |  |  |
U.S. |  | 376 |  |  | 446 |  |  | 600 |  |  | (15.5) |  |  | (25.7) |
International |  | 590 |  |  | 673 |  |  | 794 |  |  | (12.3) |  |  | (15.2) |
Worldwide |  | 966 |  |  | 1,119 |  |  | 1,394 |  |  | (13.6) |  |  | (19.7) |
TOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |
U.S. |  | 28,604 |  |  | 27,954 |  |  | 25,735 |  |  | 2.3 |  |  | 8.6 |
International |  | 23,959 |  |  | 23,726 |  |  | 19,440 |  |  | 1.0 |  |  | 22.0 |
Worldwide |  | 52,563 |  |  | 51,680 |  |  | 45,175 |  |  | 1.7 |  |  | 14.4 |
MEDTECH*(3) |  |  |  |  |  |  |  |  |  |
Interventional Solutions |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,169 |  |  | 1,836 |  |  | 1,452 |  |  | 18.2 |  |  | 26.4 |
International |  | 2,131 |  |  | 2,135 |  |  | 1,594 |  |  | (0.2) |  |  | 34.0 |
Worldwide |  | 4,300 |  |  | 3,971 |  |  | 3,046 |  |  | 8.3 |  |  | 30.4 |
Orthopaedics |  |  |  |  |  |  |  |  |  |
U.S. |  | 5,321 |  |  | 5,126 |  |  | 4,779 |  |  | 3.8 |  |  | 7.3 |
International |  | 3,267 |  |  | 3,462 |  |  | 2,984 |  |  | (5.6) |  |  | 16.0 |
Worldwide |  | 8,587 |  |  | 8,588 |  |  | 7,763 |  |  | 0.0 |  |  | 10.6 |
HIPS |  |  |  |  |  |  |  |  |  |
U.S. |  | 943 |  |  | 878 |  |  | 793 |  |  | 7.3 |  |  | 10.7 |
International |  | 571 |  |  | 602 |  |  | 487 |  |  | (5.1) |  |  | 23.6 |
Worldwide |  | 1,514 |  |  | 1,480 |  |  | 1,280 |  |  | 2.3 |  |  | 15.6 |
KNEES |  |  |  |  |  |  |  |  |  |
U.S. |  | 851 |  |  | 787 |  |  | 743 |  |  | 8.2 |  |  | 5.9 |
International |  | 508 |  |  | 538 |  |  | 427 |  |  | (5.7) |  |  | 26.1 |
Worldwide |  | 1,359 |  |  | 1,325 |  |  | 1,170 |  |  | 2.6 |  |  | 13.3 |
TRAUMA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,882 |  |  | 1,819 |  |  | 1,648 |  |  | 3.5 |  |  | 10.4 |
International |  | 989 |  |  | 1,066 |  |  | 966 |  |  | (7.2) |  |  | 10.4 |
Worldwide |  | 2,871 |  |  | 2,885 |  |  | 2,614 |  |  | (0.5) |  |  | 10.4 |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,645 |  |  | 1,642 |  |  | 1,595 |  |  | 0.2 |  |  | 2.9 |
International |  | 1,198 |  |  | 1,256 |  |  | 1,104 |  |  | (4.6) |  |  | 13.8 |
Worldwide |  | 2,843 |  |  | 2,898 |  |  | 2,699 |  |  | (1.9) |  |  | 7.4 |
Surgery |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,897 |  |  | 3,867 |  |  | 3,249 |  |  | 0.8 |  |  | 19.0 |
International |  | 5,793 |  |  | 5,945 |  |  | 4,983 |  |  | (2.6) |  |  | 19.3 |
Worldwide |  | 9,690 |  |  | 9,812 |  |  | 8,232 |  |  | (1.2) |  |  | 19.2 |
ADVANCED |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,784 |  |  | 1,761 |  |  | 1,535 |  |  | 1.3 |  |  | 14.9 |
International |  | 2,785 |  |  | 2,861 |  |  | 2,304 |  |  | (2.6) |  |  | 24.1 |
Worldwide |  | 4,569 |  |  | 4,622 |  |  | 3,839 |  |  | (1.1) |  |  | 20.4 |
GENERAL |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,113 |  |  | 2,105 |  |  | 1,714 |  |  | 0.4 |  |  | 22.7 |
International |  | 3,008 |  |  | 3,085 |  |  | 2,679 |  |  | (2.5) |  |  | 15.2 |
Worldwide |  | 5,121 |  |  | 5,190 |  |  | 4,392 |  |  | (1.3) |  |  | 18.1 |
Vision |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,990 |  |  | 1,857 |  |  | 1,557 |  |  | 7.2 |  |  | 19.3 |
International |  | 2,859 |  |  | 2,831 |  |  | 2,362 |  |  | 1.0 |  |  | 19.8 |
Worldwide |  | 4,849 |  |  | 4,688 |  |  | 3,919 |  |  | 3.4 |  |  | 19.6 |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,522 |  |  | 1,398 |  |  | 1,213 |  |  | 8.9 |  |  | 15.2 |
International |  | 2,022 |  |  | 2,043 |  |  | 1,781 |  |  | (1.0) |  |  | 14.7 |
Worldwide |  | 3,543 |  |  | 3,440 |  |  | 2,994 |  |  | 3.0 |  |  | 14.9 |
SURGICAL |  |  |  |  |  |  |  |  |  |
U.S. |  | 468 |  |  | 459 |  |  | 344 |  |  | 2.0 |  |  | 33.5 |
International |  | 837 |  |  | 788 |  |  | 581 |  |  | 6.2 |  |  | 35.7 |
Worldwide |  | 1,306 |  |  | 1,248 |  |  | 925 |  |  | 4.6 |  |  | 34.9 |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |
U.S. |  | 13,377 |  |  | 12,686 |  |  | 11,036 |  |  | 5.4 |  |  | 14.9 |
International |  | 14,050 |  |  | 14,374 |  |  | 11,923 |  |  | (2.3) |  |  | 20.6 |
Worldwide |  | 27,427 |  |  | 27,060 |  |  | 22,959 |  |  | 1.4 |  |  | 17.9 |
WORLDWIDE |  |  |  |  |  |  |  |  |  |
U.S. |  | 48,580 |  |  | 47,156 |  |  | 43,133 |  |  | 3.0 |  |  | 9.3 |
International |  | 46,363 |  |  | 46,619 |  |  | 39,451 |  |  | (0.6) |  |  | 18.2 |
Worldwide |  | $ | 94,943 |  |  | 93,775 |  |  | 82,584 |  |  | 1.3 | % |  | 13.6 |
*Certain prior year amounts have been reclassified to conform to current year presentation **Percentage greater than 100% or not meaningful (1)Approximately $0.4 billion in both the fiscal 2021 and 2020, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (2) Inclusive of PROCRIT / EPREX which was previously disclosed separately (3) Pr eviously referred to as Medical Devices |
Schedule of Segment Reporting Information |
|  | Income (Loss) Before Tax* |  | Identifiable Assets
(Dollars in Millions) |  | 2022 (3) |  | 2021 (4) |  | 2020 (5) |  | 2022 |  | 2021
Consumer Health |  | $ | 2,930 |  |  | 1,573 |  |  | (852) |  |  | $ | 24,068 |  |  | 25,081 |
Pharmaceutical |  | 15,901 |  |  | 17,969 |  |  | 15,250 |  |  | 58,436 |  |  | 64,376 |
MedTech |  | 4,607 |  |  | 4,373 |  |  | 3,044 |  |  | 70,956 |  |  | 53,372 |
Total |  | 23,438 |  |  | 23,915 |  |  | 17,442 |  |  | 153,460 |  |  | 142,829 |
Less: Expense not allocated to segments (1) |  | 624 |  |  | 1,072 |  |  | 945 |  |  |  |  |
Less: Consumer Health separation costs |  | 1,089 |  |  | 67 |  |  |  |  |  |  |
General corporate (2) |  |  |  |  |  |  |  | 33,918 |  |  | 39,189 |
Worldwide total |  | $ | 21,725 |  |  | 22,776 |  |  | 16,497 |  |  | $ | 187,378 |  |  | 182,018 |
*Income before tax of approximately $0.2 billion and $0.2 billion in the fiscal years 2021 and 2020, respectively, has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
|  | Additions to Property, Plant & Equipment |  | Depreciation and Amortization
(Dollars in Millions) |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020
Consumer Health |  | $ | 323 |  |  | 331 |  |  | 248 |  |  | $ | 658 |  |  | 759 |  |  | 785 |
Pharmaceutical |  | 1,374 |  |  | 1,198 |  |  | 863 |  |  | 3,687 |  |  | 4,029 |  |  | 4,006 |
MedTech |  | 2,120 |  |  | 1,933 |  |  | 1,980 |  |  | 2,302 |  |  | 2,286 |  |  | 2,140 |
Segments total |  | 3,817 |  |  | 3,462 |  |  | 3,091 |  |  | 6,647 |  |  | 7,074 |  |  | 6,931 |
General corporate |  | 192 |  |  | 190 |  |  | 256 |  |  | 323 |  |  | 316 |  |  | 300 |
Worldwide total |  | $ | 4,009 |  |  | 3,652 |  |  | 3,347 |  |  | $ | 6,970 |  |  | 7,390 |  |  | 7,231 |
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas |  |
|  | Sales to Customers |  | Long-Lived Assets (6)
(Dollars in Millions) |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021
United States |  | $ | 48,580 |  |  | 47,156 |  |  | 43,133 |  |  | $ | 66,283 |  |  | 48,586 |
Europe |  | 23,449 |  |  | 23,594 |  |  | 18,980 |  |  | 38,774 |  |  | 43,257 |
Western Hemisphere excluding U.S. |  | 6,125 |  |  | 5,750 |  |  | 5,335 |  |  | 2,737 |  |  | 2,708 |
Asia-Pacific, Africa |  | 16,789 |  |  | 17,275 |  |  | 15,136 |  |  | 4,431 |  |  | 5,035 |
Segments total |  | 94,943 |  |  | 93,775 |  |  | 82,584 |  |  | 112,225 |  |  | 99,586 |
General corporate |  |  |  |  |  |  |  | 1,134 |  |  | 1,014 |
Other non long-lived assets |  |  |  |  |  |  |  | 74,019 |  |  | 81,418 |
Worldwide total |  | $ | 94,943 |  |  | 93,775 |  |  | 82,584 |  |  | $ | 187,378 |  |  | 182,018 |
See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In fiscal year 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0%, and 12.0% of the total consolidated revenues. (1)Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2)General corporate includes cash, cash equivalents and marketable securities. (3)Consumer Health includes: •Litigation expense of $0.2 billion •A restructuring related charge of $0.1 billion Pharmaceutical includes: •One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion •An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS •Litigation expense of $0.1 billion •Loss of $0.7 billion related to the change in the fair value of securities •A restructuring related charge of $0.1 billion MedTech includes: •Litigation expense of $0.6 billion primarily for pelvic mesh related costs •A restructuring related charge of $0.3 billion •Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed •A Medical Device Regulation charge of $0.3 billion (4) Consumer Health includes: •Litigation expense of $1.6 billion, primarily talc related costs •A restructuring related charge of $0.1 billion Pharmaceutical includes: •Litigation expense of $0.6 billion, primarily related to Risperdal Gynecomastia •Divestiture gains of $0.6 billion •Gains of $0.5 billion related to the change in the fair value of securities •A restructuring related charge of $0.1 billion MedTech includes: •A restructuring related charge of $0.3 billion •An in-process research and development expense of $0.9 billion related to Ottava •A Medical Device Regulation charge of $0.2 billion •Litigation expense of $0.1 billion (5) Consumer Health includes: •Litigation expense of $3.9 billion, primarily talc related costs and certain settlements. Pharmaceutical includes: •Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation •A gain of $0.5 billion related to the change in the fair value of securities •A restructuring related charge of $0.1 billion MedTech includes: •A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. •Litigation expense of $0.3 billion •A restructuring related charge of $0.3 billion •An in-process research and development expense of $0.2 billion •A Medical Device Regulation charge of $0.1 billion (6) Long-lived assets include property, plant and equipment, net for fiscal years 2022, and 2021 of $19,803 and $18,962, respectively, and intangible assets and goodwill, net for fiscal years 2022 and 2021 of $93,556 and $81,638, respectively.

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration